Martindale Pharma Launches First Ready-To-Use Presentation of Phenylephrine

Home » Martindale Pharma Launches First Ready-To-Use Presentation of Phenylephrine

Martindale Pharma Launches First Ready-To-Use Presentation of Phenylephrine

lab research moleculeMartindale Pharma, the UK-based leading international specialty pharmaceutical company, has announced the UK launch of phenylephrine, a new strength of the selective vasopressor drug for the treatment of hypotension associated with anaesthesia. From today, phenylephrine will be available in a 10 mL ampoule at a strength of 0.1 mg/mL.

This new strength not only allows for accurate dose dispensing but also provides healthcare professionals with a much needed replacement to using the concentrated alternative. To date, phenylephrine is only available as a 10 mg/mL in 1 mL ampoules, which is diluted prior to use. Martindale Pharma’s phenylephrine product offers a simpler approach to product use, and can be given as an intravenous bolus injection or as a continuous infusion without the need for dilution.

Martindale Pharma has licensed exclusive rights to a range of phenylephrine products for the UK and Gulf Co-Operation Council Countries from Unimedic AB, Martindale Pharma’s strategic partner for Scandinavia. This particular product joins the range of cardiovascular drugs within Martindale Pharma’s Emergency Care portfolio.

Michael Clark, Chief Marketing Officer of Martindale Pharma, commented: “We are pleased with this positive addition to this well-known phenylephrine range. Our novel presentation removes the need to dilute the drug prior to use allowing for more accurate dose dispensing resulting in both time and cost savings for the NHS. Our NHS price is also significantly lower than the “concentrate” product.

The launch of this ready-to-use product demonstrates Martindale Pharma commitment to providing high quality innovative products to our customers and to patients while ensuring cost-effectiveness for the NHS.”